Li Ying, Xuan Jie, Xia Tom, Han Xin, Song Yujun, Cao Zheng, Jiang Xin, Guo Yi, Wang Ping, Qin Lidong
†Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
‡Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10065, United States.
Anal Chem. 2015 Apr 7;87(7):3771-7. doi: 10.1021/ac504301y. Epub 2015 Mar 18.
Point-of-care (POC) testing has become widely used in clinical analysis because of its speed and portability; however, POC tools, such as lateral flow assays, suffer from low specificity, unclear readouts, and susceptibility to environmental and user errors. Herein, we report an ELISA-based competitive volumetric bar-chart chip (CV-chip) that eliminates these limitations. The CV-chip displays the readout in the form of ink bar charts based on direct competition between gases generated by the sample and the internal control. By employing a "competition mode", this platform decreases the potential influence of background resulting from environmental factors and provides visually clear positive or negative results without the requirement of calibration. In addition, the on-chip comparison enables the device to distinguish imperceptible differences (less than 1.3-fold) in human chorionic gonadotropin (hCG) concentrations that are near the cutoff value for pregnancy (∼1.4 ng/mL). We also utilized the ELISA-based CV-chip to successfully detect biomarkers from cancer cells. As a proof-of-concept application in a clinical setting, the CV-chip was employed to evaluate the status of drugs of abuse in 18 patients. For six different drugs, zero false-positive and very few false-negative (<2%) results were reported in more than 100 tests. This new ELISA platform offers a clinical diagnostics tool that is portable and easy to use, and provides improved clarity and sensitivity due to the inclusion of a real-time internal control.
即时检测(POC)因其速度快和便携性,已在临床分析中得到广泛应用;然而,诸如侧向流动分析等POC工具存在特异性低、读数不清晰以及易受环境和用户误差影响等问题。在此,我们报告一种基于酶联免疫吸附测定(ELISA)的竞争性体积条形图芯片(CV芯片),该芯片消除了这些局限性。CV芯片基于样品与内部对照产生的气体之间的直接竞争,以墨水条形图的形式显示读数。通过采用“竞争模式”,该平台降低了环境因素导致的背景潜在影响,无需校准即可提供视觉上清晰的阳性或阴性结果。此外,芯片上的比较使该设备能够区分人绒毛膜促性腺激素(hCG)浓度中难以察觉的差异(小于1.3倍),这些差异接近妊娠临界值(约1.4 ng/mL)。我们还利用基于ELISA的CV芯片成功检测了癌细胞中的生物标志物。作为在临床环境中的概念验证应用,CV芯片用于评估18例患者的药物滥用状况。对于六种不同的药物,在100多次检测中报告的假阳性为零,假阴性结果极少(<2%)。这种新的ELISA平台提供了一种便携且易于使用的临床诊断工具,并且由于包含实时内部对照,提高了清晰度和灵敏度。